Clinical Trial Update: Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer. [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial compares switch maintenance with gemcitabine plus nab-paclitaxel to continuation of modified FOLFIRINOX as first-line therapy for adv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Gemcitabine (Gemcitabine)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• Nab-paclitaxel (paclitaxel protein-bound)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Gruppo Oncologico del Nord-Ovest | Conditions: Pancreatic Adenocarcinoma Advanced or Metastatic | Phase 3 | Status: RECRUITING